Companhia Brasileira de Distribui̤̣o (CBD) EPS Estimated At $0.25; Biocept (BIOC) Shorts Down By 39.22% РD Minute

Analysts expect Companhia Brasileira de Distribuição (NYSE:CBD) to report $0.25 EPS on February, 18.They anticipate $0.08 EPS change or 47.06% from last quarter’s $0.17 EPS. CBD’s profit would be $66.57 million giving it 25.09 P/E if the $0.25 EPS is correct. After having $0.13 EPS previously, Companhia Brasileira de Distribuição’s analysts see 92.31% EPS growth. The stock decreased 0.71% or $0.18 during the last trading session, reaching $25.09. About 486,624 shares traded. Companhia Brasileira de Distribuição (NYSE:CBD) has declined 6.64% since February 11, 2018 and is downtrending. It has underperformed by 6.64% the S&P500. Some Historical CBD News: 27/03/2018 – AMAZON-CASINO DEAL IN BRAZIL COULD BE STRUCTURED LIKE MONOPRIX PARTNERSHIP OR AS OUTRIGHT SALE OF VIA VAREJO; 13/04/2018 – Brazil’s GPA says quarterly income rises 7.5 percent; 15/05/2018 – MONOPRIX CASP.PA EXPECTS TO MULTIPLY BY FIVE ITS ONLINE REVENUE IN NEXT THREE YEARS – MONOPRIX CEO SCHULTZ; 17/04/2018 – CASINO CFO SAYS SALE PROCESS FOR VIA VAREJO UNIT CONTINUES , NOTHING NEW TO REPORT AT THIS STAGE; 27/03/2018 – AMAZON.COM AND FRENCH RETAILER CASINO DISCUSSING POSSIBLE BRAZIL DEAL; 17/04/2018 – CASINO CASP.PA KEEPS 2018 FINANCIAL GOALS – CFO; 27/03/2018 – Amazon, Casino eye partnership or sale for electronics chain; 26/04/2018 – Brazil electronics chain Via Varejo misses quarterly profit estimates; 17/04/2018 – CASINO CFO REITERATES EXPECTS GEANT HYPERMARKETS TO BE PROFITABLE IN 2018; 27/03/2018 – Amazon in talks with Casino over Brazil electronics chain

Biocept Inc (NASDAQ:BIOC) had a decrease of 39.22% in short interest. BIOC’s SI was 266,200 shares in February as released by FINRA. Its down 39.22% from 438,000 shares previously. With 66,300 avg volume, 4 days are for Biocept Inc (NASDAQ:BIOC)’s short sellers to cover BIOC’s short positions. The SI to Biocept Inc’s float is 12.06%. The stock decreased 47.29% or $0.96 during the last trading session, reaching $1.07. About 8.74M shares traded or 286.18% up from the average. Biocept, Inc. (NASDAQ:BIOC) has declined 95.76% since February 11, 2018 and is downtrending. It has underperformed by 95.76% the S&P500. Some Historical BIOC News: 28/03/2018 – BIOCEPT INC – ENTERED INTO A NON-BINDING MEMORANDUM OF UNDERSTANDING WITH THERMO FISHER SCIENTIFIC, INC. TO COLLABORATE TOGETHER COMMERCIALLY; 28/03/2018 – Biocept 4Q Loss/Shr 18c; 28/03/2018 – BIOCEPT, THERMO FISHER SCIENTIFIC ANNOUNCE PACT; 29/03/2018 – BIOCEPT GETS PATENT FOR MOLECULAR BIOMARKER TECHNOLOGY IN CHINA; 06/04/2018 – Biocept to Webcast Presentation at the 7th Annual MicroCap Conference; 28/03/2018 – Biocept and Thermo Fisher Scientific Enter into Technology and Commercial Collaboration; 28/03/2018 – Biocept and Thermo Fisher Scientific Enter Into Technology and Comml Collaboration; 28/03/2018 – BIOCEPT – PLAN TO VALIDATE THERMO FISHER’S ONCOMINE NEXT-GENERATION SEQUENCING LIQUID BIOPSY PANELS IN BIOCEPT’S CLIA-CERTIFIED LABORATORY; 28/03/2018 – BIOCEPT, THERMO PACT TO EVALUATE TARGET SELECTOR FEASIBILITY; 29/03/2018 – Biocept Obtains Patent for its Target Selector Molecular Biomarker Technology in China

More notable recent Biocept, Inc. (NASDAQ:BIOC) news were published by: which released: “Biocept up 21% premarket on Agiomix deal – Seeking Alpha” on February 07, 2019, also with their article: “Health Care Sector Update for 02/08/2019: BIOC,QURE,SGEN – Nasdaq” published on February 08, 2019, published: “Health Care Sector Update for 02/08/2019: INGN,BIOC,QURE,SGEN – Nasdaq” on February 08, 2019. More interesting news about Biocept, Inc. (NASDAQ:BIOC) were released by: and their article: “Biocept prices $2.2M registered direct offering – Seeking Alpha” published on January 18, 2019 as well as‘s news article titled: “Biocept files for equity offering; shares down 10% – Seeking Alpha” with publication date: January 29, 2019.

Biocept, Inc., an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating tumor DNA assays utilizing a standard blood sample. The company has market cap of $4.95 million. The companyÂ’s cancer assays provide information to oncologists and other physicians that enable them to select personalized treatment for their patients who have been diagnosed with cancer based on molecular drivers. It currently has negative earnings. It offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer, small cell lung cancer, gastric cancer, colorectal cancer, prostate cancer, and melanoma.

Companhia Brasileira de Distribui????o engages in the retail of food, clothing, home appliances, electronics, and other products through its chain of hypermarkets, supermarkets, specialized stores, and department stores primarily in Brazil. The company has market cap of $6.68 billion. The firm operates through two divisions, Food Retail; and Cash and Carry. It has a 23.19 P/E ratio. The Food retail segment sells non-perishable food products, beverages, fruits, vegetables, meat, breads, cold cuts, dairy products, cleaning products, disposable products, and personal care products; and non-food products, which include clothing items, baby items, shoes and accessories, household articles, books, magazines, CDs and DVDs, stationery, handcrafts, toys, sports and camping gears, furniture, mattresses, pet products, and gardening products, as well as electronic products, such as personal computers, software, computer accessories, and sound and image systems.

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.


« »